A nurse is caring for a client who has chronic renal disease and is receiving therapy with epoetin alfa (Epogen). Which of the following laboratory results would the nurse assess for to determine therapeutic effectiveness?

A. ALT & AST: ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes that are typically used to assess liver function and detect liver damage. Epoetin alfa (Epogen) is a medication used to stimulate red blood cell production in patients with anemia, particularly in those with chronic renal disease. While liver function may be important in overall health monitoring, ALT and AST levels are not directly relevant to evaluating the effectiveness of epoetin alfa therapy. B. Leukocyte count: Leukocyte count measures the number of white blood cells and is used to assess immune function or detect infections. Epoetin alfa does not have a direct effect on white blood cell production, and therefore, monitoring the leukocyte count is not the best indicator for determining the effectiveness of epoetin alfa therapy, which is primarily concerned with red blood cell production. C. Hemoglobin & hematocrit: Epoetin alfa (Epogen) is used to stimulate the production of red blood cells and treat anemia, particularly in patients with chronic kidney disease or those undergoing chemotherapy. The therapeutic effectiveness of epoetin alfa is most commonly assessed by monitoring the hemoglobin and hematocrit levels, as these are direct indicators of red blood cell count and oxygen-carrying capacity. An increase in these values suggests that the medication is effective in treating anemia. D. Clotting Factors: Clotting factors are proteins in the blood that help control bleeding. While epoetin alfa can increase red blood cell production, it is not directly associated with changes in clotting factors. In fact, there is a potential risk of increased thromboembolic events (e.g., blood clots) with epoetin alfa, particularly if hemoglobin levels rise too rapidly, but monitoring clotting factors is not the primary way to assess the drug's effectiveness. Monitoring hemoglobin and hematocrit levels is the more appropriate strategy.